MSGV1-PSCA-8T28Z / H. Lee Moffitt Cancer Center and Research Institute - LARVOL DELTA

Moffitt Treats First Clinical Trial Patient with Gamma Delta CAR T for Bone Metastatic Prostate Cancer (Moffitt Cancer Center) - "Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone....This is a single-center phase 1 dose-escalation trial with a 3+3 design. In a 3+3 design, three patients are enrolled into a cohort for a given dose. If no dose-limiting toxicities exist in the cohort, the trial enrolls additional participants into the next higher dose cohort."

Trial status • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PSCA

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Metastases • New P1 trial • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PSCA